Influence of olanzapine on cognitive functions and catalepsy in rats after single and chronic administration

Polish Journal of Pharmacology

Volumn 51, Issue 4, 1999, Pages 295-300

  Nowakowska, Elzbieta ^a   Chodera, Alfons ^a   Kus, Krzysztof ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Catalepsy; Cognitive functions; Olanzapine

Indexed keywords

ANXIOLYTIC AGENT; DOPAMINE 2 RECEPTOR; OLANZAPINE; SEROTONIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CATALEPSY; COGNITION; CONTROLLED STUDY; DRUG POTENCY; IMMOBILIZATION; INTRAPERITONEAL DRUG ADMINISTRATION; LONG TERM CARE; MALE; MAZE TEST; MEMORY; NONHUMAN; RAT; SWIMMING;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BENZODIAZEPINES; CATALEPSY; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; MALE; MAZE LEARNING; MEMORY; MOTOR ACTIVITY; PIRENZEPINE; RATS; RATS, WISTAR; SEROTONIN UPTAKE INHIBITORS;

EID: 0032857099     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Baldacchino A. M., Stubbs J. H, Nevison-Andrews D.: The use of olanzapine in non-compliant or treatment-resistant clozapine populations in hospital. Pharm. J., 1998, 360, 207-209.
2. Bymaster F. P., Calligaro D. O., Falcone J. F., Marsh R. D., Moore N. A., Tye N. C., Seeman P., Wong D. T.: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology, 1996, 14, 87-96.
3. Charney D.: What makes olanzapine "a novel" antipsychotic? Preclinical pharmacology. Abstracts of 6th World Congress of Biological Psychiatry, Nice, France, 1997, 3-15.
4. Crawley J. N.: Neuropsychopharmacological specificity of a single animal model for the behavioural action of benzodiazepines. Pharmacol. Biochem. Behav., 1981, 15, 695-699.
5. Hagger C., Buckley P., Henny J. T.: Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenia patients receiving clozapine. Biol. Psychiat., 1993, 34, 702-712.
6. Ishida-Tokuda K., Ohno Y., Sakamoto H. Ishibashi T., Wakabayashi J., Tojima R., Morita T., Nakamura M.: Evaluation of perospirone (SM-9018), a novel serotonin-2 and dopamine-2 receptor antagonist, and other antipsychotics in the conditioned fear stress-induced freezing behavior model in rats. Jpn. J. Pharmacol., 1996, 72, 119-126.
7. King D. J.: Drugs treatment of the negative symptoms of schizophrenia Eur. Neuropsychopharmacol., 1998, 8, 33-42.
8. Mc Gurck S. R., Green M. F., Marder S. R., Santana S., Mc Gee M., Waters G.: Risperidone versus haloperidol on spatial working memory. News & News, 1999, Vol. 4, Suppl. 1.
9. Moore N. A., Leander J. D., Benvenga M. J., Gleason S. D., Shannon H.: Behavioral pharmacology of olanzapine: a novel antipsychotic drug. J. Clin. Psychiat., 1997, 58, Suppl. 10, 37-44.
10. Moore N. A., Tye N. C., Axton M. S, Risius F. C.: The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J. Pharmacol. Exp. Ther., 1992, 262, 545-551.
11. Porsolt R. D., Anton G., Blavet N., Jalfre M.: Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur. J. Pharmacol., 1978, 47, 379-391.
12. Remington G. J., Prandergast P., Bezchlibnykbutler K. Z.: Neuroleptic dosing in chronic schizophrenia - a 10 years follow up. Can. J. Psychiat., 1996, 41, 1S-9S.
13. Ther L.: Grundlagen der Experimenteller Arzneimittelforschung. Stuttgart, Wissenschaftliche Verlagsgesellschaft, 1965.
14. Tollefson G. D., Beasley Ch. M., Tamura R. N., Tran P. V., Potvin J. H.: Blind controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Amer. J. Psychiat., 1997, 154, 1248-1254.
15. Tollefson G. D., Beasley Ch. M., Tran P. V., Street J. S., Krueger J. A., Tamura R. N., Graffeo K. A., Thieme M. E.: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Amer. J. Psychiat., 1997, 154, 457-465.
16. Tran P. V. Hamilton S. H., Kuntz A. J., Potvin J. H., Andersen S. W., Beasley C., Tollefson G. D.: Double blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. Psychopharmacol, 1997, 11, 407-418.
17. Tran P. V., Dellva M. A., Tollefson G. D., Beasley C. M., Potvin J. H., Kiesler G. M.: Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J. Clin. Psychiat., 1997, 58, 205-211.
18. 2 dopamine receptors in the neuroleptic catalepsy in rats. Pol. J. Pharmacol. 1995, 47, 349-353.
19. Wood A.: Clinical experience with olanzapine, a new atypical antipsychotic. Int. Clin. Psychopharmacol., 1998, 13 Suppl., S.59-S.62.
20. Zarate C. A., Narendran R., Tohen M., Greaney J. J., Berman A., Pike S., Madrid A.: Clinical predictors of acute response with olanzapine in psychotic mood disorders. J. Clin. Psychiat., 1998, 59, 24-28.